3711 related articles for article (PubMed ID: 7456419)
21. Pregnancy and early-stage melanoma.
Daryanani D; Plukker JT; De Hullu JA; Kuiper H; Nap RE; Hoekstra HJ
Cancer; 2003 May; 97(9):2248-53. PubMed ID: 12712479
[TBL] [Abstract][Full Text] [Related]
22. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival.
Dai DL; Makretsov N; Campos EI; Huang C; Zhou Y; Huntsman D; Martinka M; Li G
Clin Cancer Res; 2003 Oct; 9(12):4409-14. PubMed ID: 14555513
[TBL] [Abstract][Full Text] [Related]
24. Prognosis and staging in melanoma.
Garrison M; Nathanson L
Semin Oncol; 1996 Dec; 23(6):725-33. PubMed ID: 8970594
[TBL] [Abstract][Full Text] [Related]
25. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
26. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society.
Buettner PG; Leiter U; Eigentler TK; Garbe C
Cancer; 2005 Feb; 103(3):616-24. PubMed ID: 15630700
[TBL] [Abstract][Full Text] [Related]
27. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
28. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
29. Malignant melanoma.
Califano J; Nance M
Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
[TBL] [Abstract][Full Text] [Related]
30. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors.
Prasad ML; Patel SG; Huvos AG; Shah JP; Busam KJ
Cancer; 2004 Apr; 100(8):1657-64. PubMed ID: 15073854
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
32. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
33. A long-term analysis of 620 patients with malignant melanoma at a major referral center.
Averbook BJ; Russo LJ; Mansour EG
Surgery; 1998 Oct; 124(4):746-55; discussion 755-6. PubMed ID: 9780997
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
35. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
36. Malignant melanoma in pregnancy. A population-based evaluation.
O'Meara AT; Cress R; Xing G; Danielsen B; Smith LH
Cancer; 2005 Mar; 103(6):1217-26. PubMed ID: 15712209
[TBL] [Abstract][Full Text] [Related]
37. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
38. Classification of localized melanoma by the exponential survival trees method.
Huang X; Soong S; McCarthy WH; Urist MM; Balch CM
Cancer; 1997 Mar; 79(6):1122-8. PubMed ID: 9070489
[TBL] [Abstract][Full Text] [Related]
39. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
40. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
Barnhill RL; Fine JA; Roush GC; Berwick M
Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
